Turkish Study Reveals Major Gaps in Childhood Heart Disease Prevention

Familial hypercholesterolemia affects roughly 1 in 250 people worldwide, causing dangerously high cholesterol levels from birth and dramatically increasing heart disease risk. Despite its prevalence, most cases remain undiagnosed in childhood, missing critical intervention windows.

Turkish researchers analyzed 124 children with genetically confirmed heterozygous familial hypercholesterolemia, examining diagnosis patterns, genetic variants, and treatment outcomes. They sequenced three key genes (LDLR, APOB, PCSK9) and tracked patient responses to different statin medications over time.

The results revealed significant healthcare system failures. Only 28% of patients were diagnosed through routine screening, despite 90% having positive family histories. After diagnosis, 16% declined treatment and 41% were lost to follow-up. Most cases involved pathogenic LDLR gene variants, with researchers identifying three previously unknown mutations. Among treated patients, both atorvastatin and pitavastatin effectively reduced LDL cholesterol levels, with atorvastatin showing greater median reductions. Side effects were minimal, with only five patients experiencing temporary muscle enzyme elevations.

These findings highlight critical gaps in pediatric cardiovascular prevention. Early statin treatment in children with familial hypercholesterolemia can prevent heart attacks and extend lifespan by decades. The study demonstrates that genetic testing enables precise diagnosis and that modern statins are safe and effective in children. However, systematic screening programs, family education, and consistent follow-up remain inadequate globally, not just in developing countries. This represents a massive missed opportunity for longevity optimization through early intervention.